Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 510 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Schizophrenia Schizoaffective Clear all

Conditions: Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
Interventions: mobile application; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: West Los Angeles, California

Conditions: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: Targeted cognitive training (TCT), Computer games; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes, Obesity, Weight Gain
Interventions: Lifestyle Balance; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Long Beach, California • Sepulveda, California • West Los Angeles, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Sensoril®, Placebo; Drug
Lead sponsor: K.N. Roy Chengappa; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Psychotic Disorders
Interventions: Observational; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Obesity, Schizophrenia, Schizoaffective Disorder
Interventions: Naltrexone 25mg, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions: Life Goals Collaborative Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: adjunctive treatment with buspirone, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions: Intranasal Insulin; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: Nicotine patch; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Piscataway, New Jersey

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: olanzapine, risperidone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions: genetic analysis, genetic assay; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: ziprasidone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 28
States / cities: Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 23 more

Conditions: Schizophrenia, Schizoaffective Disorder, Social Anxiety Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: curcumin 1800mg, Placebo; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
Interventions: iTBS (Active), iTBS (Sham); Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia
Interventions: Antipsychotic/Risperidone Consta; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Butner, North Carolina • Durham, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: Dipyridamole, Olanzapine; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions: Exercise Intervention- PACE-Life; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder, Major Depression
Interventions: Family Member Provider Outreach, Enhanced treatment as usual (e-TAU); Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: West Los Angeles, California • Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: ziprasidone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

Mobile Self-Tracking of Mental Health

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia

Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

Serotonin 1A Agonists and Cognition in Schizophrenia

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia

iTBS to Enhance Social Cognition in People With Psychosis

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Clinical Trial of Dipyridamole in Schizophrenia

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life

The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone